The Impact of COVID-19 on Patient–Doctor Communication
CLL Monthly MinutesLeukemia
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits.
Fewer Surprise Medical Bills Starting in 2022
CLL Monthly MinutesLeukemia
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services.
Improved Combination Therapies May Be Coming for Patients with CLL
CLL Monthly MinutesLeukemia
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study.
Evolving Cancer Care in the Time of COVID-19
CLL Monthly MinutesLeukemia
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered.
Retrospective Analysis Suggests Higher Risk of Secondary Cancers with BTK Inhibitors in CLL
CLL Monthly MinutesLeukemia
Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population.
FDA Approvals, News & UpdatesLeukemia
The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL).
Drugs for Leukemia
Here are the drugs and financial support services available to patients receiving treatment for Leukemia.
Expanded Options for Treating Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Targeted therapies continue to change the treatment landscape, improving outcomes beyond traditional chemoimmunotherapy.
Costs of Healthcare Plans Projected to Continue Increasing in 2021
CLL Monthly MinutesLeukemia
Although most employers are not passing costs to employees, the COVID-19 pandemic has raised uncertainty throughout the entire healthcare system.
Low Risk of Cardiac Side Effects with Acalabrutinib for Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
An analysis of 4 studies finds that acalabrutinib does not increase the risk of developing heart problems for patients with CLL.
Page 1 of 9
Results 1 - 10 of 84

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.